Last reviewed · How we verify
ENZ215
ENZ215 is an investigational therapeutic targeting a specific molecular pathway in early-to-mid stage clinical development by Enzene Biosciences.
At a glance
| Generic name | ENZ215 |
|---|---|
| Sponsor | Enzene Biosciences Ltd. |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available on ENZ215's precise mechanism of action. As a Phase 3 candidate from Enzene Biosciences, it is undergoing advanced clinical testing, but detailed mechanistic data, molecular targets, and therapeutic indications have not been widely disclosed in accessible literature.
Approved indications
Common side effects
Key clinical trials
- A Phase 3 Study to Compare Biosimilar Denosumab With Prolia® (PHASE3)
- Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ENZ215 CI brief — competitive landscape report
- ENZ215 updates RSS · CI watch RSS
- Enzene Biosciences Ltd. portfolio CI